Artículos de revistas
Successful Improvement of Frequency and Symptoms of Premature Complexes after Oral Magnesium Administration
Fecha
2012Registro en:
ARQUIVOS BRASILEIROS DE CARDIOLOGIA, RIO DE JANEIRO, v. 98, n. 6, supl., Part 1-2, pp. 480-487, JUN, 2012
0066-782X
Autor
Muniz Lima De Falco, Cristina Nadja
Grupi, Cesar
Sosa, Eduardo
Scanavacca, Mauricio
Hachul, Denise
Lara, Sissy
Sacilotto, Luciana
Pisani, Cristiano F.
Ramires, Jose A. F.
Darrieux, Francisco
Institución
Resumen
Background: Premature ventricular and supraventricular complexes (PVC and PsVC) are frequent and often symptomatic. The magnesium (Mg) ion plays a role in the physiology of cell membranes and cardiac rhythm. Objective: We evaluated whether the administration of Mg Pidolate (MgP) in patients with PVC and PsVC is superior to placebo (P) in improving symptoms and arrhythmia frequency. Methods: Randomized double-blind study with 60 consecutive symptomatic patients with more than 240 PVC or PsVC/h on 24-hour Holter monitoring who were selected to receive placebo or MgP. To evaluate symptom improvement, a categorical and a specific questionnaire for symptoms related to PVC and PsVC was made. Improvement in premature complex density (PCD) per hour was considered significant if percentage reduction was >= 70% after treatment. The dose of MgP was 3.0 g/day for 30 days, equivalent to 260mg of Mg element. None of the patients had structural heart disease or renal failure. Results: Of the 60 patients, 33 were female (55%). Ages ranged from 16 to 70 years old. In the MgP group, 76.6% of patients had a PCD reduction >70%, 10% of them >50% and only 13.4% <50%. In the P group, 40% showed slight improvement, <30%, in the premature complexes frequency (p < 0.001). Symptom improvement was achieved in 93.3% of patients in the MgP group, compared with only 16.7% in the P group (p < 0.001). Conclusion: Oral Mg supplementation decreases PCD, resulting in symptom improvement. (Arq Bras Cardiol 2012;98(6):480-487)